Public Release: 

Malaria combination drug therapy for children

PLOS

A drug combination of artemisinin-naphthoquine should be considered for the treatment of children with uncomplicated malaria in settings where multiple parasite species cause malaria according to Tim Davis from University of Western Australia, Fremantle, Australia and colleagues in new research published in this week's PLOS Medicine.

Malaria is a mosquito-borne parasitic disease that kills approximately 600,000 people every year. Several different parasite species cause malaria and in some settings, such as Papua New Guinea, two species, Plasmodium falciparum and Plasmodium vivax, are responsible for the majority of malaria infections. However, the two species respond differently to currently available anti-malarial drugs.

The authors compared the current recommended therapy for uncomplicated malaria in children in Papua New Guinea, artemether-lumefantrine, with a different combination therapy, artemisinin-naphthoquine. Using a randomized, controlled trial study design including 186 children with Plasmodium falciparum infections and 47 children with Plasmodium vivax infections, the researchers found that artemisinin-naphthoquine was non-inferior to (no worse than) artemether-lumefantrine for treating Plasmodium falciparum (a difference of 2.2% [95% confidence interval ?3.0% to 8.4%] for reappearance of infection within 42 days) but was more effective for treating Plasmodium vivax (a difference 70.0% [95% confidence interval 40.9%-87.2%] for reappearance of infection within 42 days).

The authors conclude, "[t]he efficacy, tolerability, and safety of three daily doses of artemisinin-naphthoquine suggest that this regimen should be considered together with other currently available effective [artemisinin combination therapies] for treatment of uncomplicated malaria in [Papua New Guinea] and similar epidemiologic settings with transmission of multiple Plasmodium species."

###

Research Article

Funding: National Health and Medical Research Council (NHMRC https://www.nhmrc.gov.au/) grant #634343. Individual authors were supported by NHMRC funding: BRM by an Early Career Fellowship (#1036951), LJR an Early Career Fellowship (#1016443), IM a Senior Research Fellowship (#1043345), and TMED a Practitioner Fellowship (#572561). ML was supported by an Australian Award PhD Scholarship (http://studyassist.gov.au/sites/studyassist/scholarshipsandawards/pages/australian-postgraduate-awards), and TK was supported by an Esso-Highlands PNGIMR scholarship (http://www.pngimr.org.pg/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Citation: Laman M, Moore BR, Benjamin JM, Yadi G, Bona C, et al. (2014) Artemisinin-Naphthoquine versus Artemether-Lumefantrine for Uncomplicated Malaria in Papua New Guinean Children: An Open-Label Randomized Trial. PLoS Med 11(12): e1001773. doi:10.1371/journal.pmed.1001773

Author Affiliations:

School of Medicine and Pharmacology, University of Western Australia, AUSTRALIA

Papua New Guinea Institute of Medical Research, PAPUA NEW GUINEA

Walter and Eliza Hall Institute, AUSTRALIA

Center de Recerca en Salut Internacional de Barcelona, SPAIN

Contact:

Tim Davis
University of Western Australia
AUSTRALIA
+61 8 9431 3229
tim.davis@uwa.edu.au

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.